Top Buy Now Summary References
Home
>
Section
>
Chapter

Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin

Torres-Durán, M.ía.; López-Campos, J.é L.; Calle Rubio, M.; Montero-Martínez, C.; Priegue Carrera, A.; Amaro Rodríguez, R.; Barrecheguren, M.; Barrio Guirado, M.ía.Án.; Callejas-González, F.J.; Casas-Maldonado, F.; Diab-Cáceres, L.; García-Meseguer, P.; Hernández-Pérez, J.é M.ía.; Lázaro-Asegurado, L.; Martínez-González, C.; Martínez Rivera, C.; Michel, F.J.; Montoro-Ronsano, J.é-B.; Sánchez, R.; Ortiz-Pica, M.; Parra, I.; Quintero García, J.é P.; Ruiz-Serrano-de la Espada

International Journal of Chronic Obstructive Pulmonary Disease 18: 1691-1700

2023

ISSN/ISBN: 1178-2005
PMID: 37559832
Accession: 090449092

Full-Text Article emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Summary
Administration of exogenous alpha-1 antitrypsin (AAT) is the only specific therapy for the management of pulmonary morbidity in patients with AAT deficiency. It requires weekly or biweekly intravenous infusions, which may impact patient independence and quality of life. Self-administration of AAT therapy is an alternative to reduce the burden for patients who require AAT therapy. We presented herein experts' recommendations for the implementation of a program for the self-administration of AAT. This project was conducted using a modified nominal group technique and was undertaken in two online meetings involving the participation of 25 experts: specialists in pulmonology (n=17), nurses (n=5) and hospital pharmacists (n=3). The following issues were discussed, and several recommendations were agreed upon on the following topics: a) patient profile and clinical evaluation, establishing selection criteria that should include clinical as well as social criteria; b) role of health care professionals, suggested roles for specialists in pulmonology, nurses, and hospital pharmacists; c) training by the nurse, including recommendations before initiating the training and the content of the training sessions; and d) logistic issues and follow-up, adherence, and patient support. We expect this proposal to increase awareness of this therapeutic alternative and facilitate the implementation of self-administration programs, thus contributing to optimizing the patient experience with AAT therapy. Further research on the outcomes of these programs, especially from the patient perspective, will also help to improve their design and implementation.

References

Herth, F.J.F.; Sandhaus, R.A.; Turner, A.M.; Sucena, M.; Welte, T.; Greulich, T. 2021: Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic International Journal of Chronic Obstructive Pulmonary Disease 16: 2983-2996
O'Riordan, K.; Blei, A.; Rao, M.S.; Abecassis, M. 1997: Alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation Transplantation 63(3): 480-482
Hubbard, R.C.; Mcelvaney, G.; Sellers, S.E.; Healy, J.; Czerski, D.; Crystal, R.G. 1989: Aerosol administration of recombinant alpha antitrypsin to humans with alpha 1 antitrypsin deficiency American Review of Respiratory Disease 139(4 Part 2): A122
Curiel, D.; Brantly, M.; Curiel, E.; Stier, L.; Crystal, R.G. 1989: Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin Journal of Clinical Investigation 83(4): 1144-1152
Silverman, E.K.; Province, M.A.; Campbell, E.J.; Pierce, J.A.; Rao, D.C. 1990: Biochemical intermediates in alpha 1-antitrypsin deficiency: residual family resemblance for total alpha 1-antitrypsin, oxidized alpha 1-antitrypsin, and immunoglobulin E after adjustment for the effect of the Pi locus Genetic Epidemiology 7(2): 137-149
Hubbard, R.; Fells, G.; Cantin, A.; Ogushi, F.; Courtney, M.; Crystal, R. 1986: Recombinant dna produced valine 358 alpha 1 antitrypsin more effectively resists oxidative inactivation by alveolar macrophages of cigarette smokers than plasma derived m 1m 1 alpha 1 antitrypsin or methionine 358 alpha 1 antitrypsin American Review of Respiratory Disease 133(4 Suppl): A218
Takahashi, H.; Crystal, R.G. 1990: Alpha 1-antitrypsin Null(isola di procida): an alpha 1-antitrypsin deficiency allele caused by deletion of all alpha 1-antitrypsin coding exons American Journal of Human Genetics 47(3): 403-413
1992: Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society Cmaj: Canadian Medical Association Journal 146(6): 841-844
Wewers, M.D.; Casolaro, M.A.; Crystal, R.G. 1987: Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy American Review of Respiratory Disease 135(3): 539-543
Wewers, M.; Casolaro, A.; Sellers, S.; Mcphaul, K.; Swayze, S.; Crystal, R. 1986: Pulmonary branch national heart lung and blood institute bethesda maryland usa alpha 1 antitrypsin deficiency replacement study chronic augmentation of the antineutrophil elastase capacity of the lower respiratory tract of alpha 1 antitrypsin deficient individuals with weekly infusions of alpha 1 antitrypsin American Review of Respiratory Disease 133(4 Suppl): A103
Abbink, J.J.; Kamp, A.M.; Swaak, A.J.; Hack, C.E. 1991: Production of monoclonal antibodies against inactivated alpha 1-antitrypsin. Cross-reactivity with complexed alpha 1-antitrypsin and application in an assay to determine inactivated and complexed alpha 1-antitrypsin in biological fluids Journal of Immunological Methods 143(2): 197-208
2008: Alpha-1 Antitrypsine Humaine : Un Traitement Substitutif Sans Efficacité Établie - Human Alpha-1 Antitrypsin for Severe Alpha-1 Antitrypsin Deficiency : A Critical Study la Revue Prescrire 28(292): 92-92
Canonico, A.E.; Conary, J.T.; Meyrick, B.O.; Brigham, K.L. 1992: In vivo expression of a cmv promoter driven human alpha 1 antitrypsin alpha 1at gene after intravenous or airway administration of dna liposome complex American Review of Respiratory Disease 145(4 Part 2): A200
Whisstock, J.; Lesk, A.M.; Carrell, R. 1996: Modeling of serpin-protease complexes: antithrombin-thrombin, alpha 1-antitrypsin (358Met-->Arg)-thrombin, alpha 1-antitrypsin (358Met-->Arg)-trypsin, and antitrypsin-elastase Proteins 26(3): 288-303
Khatami, M.; Hosseini, S.N.; Hasannia, S. 2018: Co-expression of alpha-1 antitrypsin with cytoplasmic domain of v-SNARE in Pichia pastoris: Preserving biological activity of alpha-1 antitrypsin Biotechnology and Applied Biochemistry 65(2): 181-187
Brantly, M.L.; Wittes, J.T.; Vogelmeier, C.F.; Hubbard, R.C.; Fells, G.A.; Crystal, R.G. 1991: Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes Chest 100(3): 703-708
Mela, M.; Smeeton, W.; Alexander, G. 2011: The limitations of serum alpha-1 antitrypsin levels in patients with chronic liver disease and heterozygous alpha-1 antitrypsin deficiency Gut 60(Suppl 1): A57-A58
Lammens, P.; Levy, V.G.; Martin, J.P.; Feldman, G.; Caroli, J. 1974: Budd-Chiari syndrome associated with Pis or Piso type alpha 1 antitrypsin deficiency. Alpha 1 antitrypsin and the liver: review of the literature Medecine and Chirurgie Digestives 3(6): 409-415
Nukiwa, T.; Brantly, M.; Paul, L.; Garver, R.; Courtney, M.; Tolstoshev, P.; Lecocq, J.P.; Crystal, R.G. 1985: Correlation of alpha 1 antitrypsin genotype assessed by gene specific oligonucleotide probes with alpha 1 antitrypsin protein phenotype American Review of Respiratory Disease 131(4 Suppl): A372
Aldonyte, R.; Jansson, L.; Ljungberg, O.; Larsson, S.; Janciauskiene, S. 2004: Polymerized alpha-antitrypsin is present on lung vascular endothelium. new insights into the biological significance of alpha-antitrypsin polymerization Histopathology 45(6): 587-592